Last 44 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.00 | 0.06 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 4.53 | 0.56 | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 0.00 | 0.06 | — | 0.87 | 1.19 | 3.01 | 1.72 | 6.84 | 6.90 | 11.13 | 24.79 | 9.62 | 32.88 | 33.18 | 60.35 | 36.55 | 2.03 | — | — | 23.68 | — |
| — | -97.9% | — | -87.3% | -82.8% | -72.9% | -93.1% | -28.9% | -79.0% | -66.5% | -58.9% | -73.7% | +1518.2% | — | — | +54.3% | — | — | — | — | — | |
| P/B Ratio | — | — | — | — | — | — | 175.40 | 8.53 | 4.46 | 3.68 | 5.29 | 1.45 | — | — | — | 0.70 | 0.95 | 0.99 | 16.42 | 44.05 | — |
| — | — | — | — | — | — | +3213.8% | +488.3% | — | — | — | +108.5% | — | — | — | -98.4% | — | — | — | +1220.3% | — | |
| P/FCF | — | 1.51 | — | — | — | — | — | — | — | — | — | — | — | — | — | 0.89 | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | 0.05 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -0.00 | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | 0.05 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -0.00 | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | -204.0% | 100.0% | — | 100.0% | 81.7% | 100.0% | -66.4% | -414.0% | 51.4% | -410.9% | -420.2% | 78.3% | -384.6% | -503.5% | -425.8% | 73.5% | 99.9% | — | — | -85.9% | — |
| — | 0.0% | — | +124.2% | +58.9% | +124.3% | +84.2% | -629.1% | +113.4% | +18.4% | +1.3% | +6.5% | -484.9% | — | — | +185.6% | — | — | — | — | — | |
| Operating Margin | -316.7% | 96.8% | — | -250.3% | -488.8% | -388.3% | -126.9% | -574.3% | -523.4% | -583.9% | -588.9% | -708.4% | -410.7% | -649.8% | -515.5% | -1235.5% | 21.8% | — | — | -305.7% | — |
| — | +124.9% | — | +56.4% | +6.6% | +33.5% | +78.5% | +18.9% | -27.5% | +10.1% | -14.2% | +42.7% | -1982.1% | — | — | -304.2% | — | — | — | — | — | |
| Net Margin | -308.1% | 98.8% | — | -248.5% | -482.8% | -375.2% | -121.4% | -558.7% | -488.6% | -559.3% | -558.3% | -759.9% | -448.6% | -710.9% | -549.3% | -1376.2% | 44.7% | — | — | -1288.0% | — |
| — | +126.3% | — | +55.5% | +1.2% | +32.9% | +78.3% | +26.5% | -8.9% | +21.3% | -1.6% | +44.8% | -1103.2% | — | — | -6.8% | — | — | — | — | — |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | — | -198.3% | -101.4% | -57.6% | -37.9% | -26.0% | -28.6% | — | — | -17.2% | -6.6% | 5.4% | -9.7% | -31.0% | -258195.3% | — |
| — | — | — | — | — | — | -662.3% | -254.2% | — | — | -51.2% | -336.0% | — | — | +44.6% | +100.0% | — | — | +90.7% | -114717.5% | — | |
| ROA | -100.8% | 773.2% | -93.2% | -39.9% | -48.6% | -25.1% | -16.8% | -23.2% | -21.3% | -17.9% | -13.7% | -21.6% | -20.9% | -19.8% | -9.2% | -4.2% | 3.3% | -4.3% | -4.3% | -29.6% | -10.1% |
| — | +3186.3% | -456.1% | -71.8% | -127.8% | -40.4% | -22.0% | -7.6% | -2.0% | +9.9% | -49.6% | -413.8% | -741.8% | -360.7% | -115.9% | +85.8% | +132.3% | +80.0% | +83.4% | -178.0% | +64.8% | |
| ROIC | — | — | — | — | — | — | — | — | — | — | -129.2% | -59.9% | — | — | -734.9% | -126.1% | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | +82.4% | +52.5% | — | — | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | 10.44 | 0.69 | 0.12 | 0.06 | 0.08 | 0.06 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | +13225.3% | +981.4% | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Debt / EBITDA | — | 0.02 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 1.48 | 0.86 | 0.48 | 1.34 | 1.48 | 3.23 | 3.25 | 4.64 | 5.06 | 7.53 | 6.80 | 6.73 | 2.78 | 1.35 | 6.40 | 21.32 | 17.77 | 15.92 | 9.30 | 7.29 | 3.48 |
| — | -73.3% | -85.2% | -71.2% | -70.7% | -57.1% | -52.2% | -31.1% | +82.3% | +456.0% | +6.3% | -68.4% | -84.4% | -91.5% | -31.2% | +192.5% | +410.3% | +215.1% | +46.1% | +19.6% | -45.5% | |
| Quick Ratio | 1.48 | 0.86 | 0.48 | 1.34 | 1.48 | 3.23 | 3.25 | 4.64 | 5.06 | 7.53 | 6.80 | 6.73 | 2.78 | 1.35 | 6.40 | 21.32 | 17.77 | 15.92 | 9.30 | 7.29 | 3.48 |
| — | -73.3% | -85.2% | -71.2% | -70.7% | -57.1% | -52.2% | -31.1% | +82.3% | +456.0% | +6.3% | -68.4% | -84.4% | -91.5% | -31.2% | +192.5% | +410.3% | +215.1% | +46.1% | +19.6% | -45.5% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | -15.61 | -17.67 | -18.45 | -18.07 | -9.27 | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 44 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CARM stock.
Carisma Therapeutics, Inc.'s current P/E is -0.0x. The average P/E over the last 1 quarters is 0.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Carisma Therapeutics, Inc.'s current operating margin is -316.7%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Carisma Therapeutics, Inc.'s business trajectory between earnings reports.